IL152989A0 - Use of riluzole or its salts for preventing and treating ?noleukodystrophy - Google Patents

Use of riluzole or its salts for preventing and treating ?noleukodystrophy

Info

Publication number
IL152989A0
IL152989A0 IL15298901A IL15298901A IL152989A0 IL 152989 A0 IL152989 A0 IL 152989A0 IL 15298901 A IL15298901 A IL 15298901A IL 15298901 A IL15298901 A IL 15298901A IL 152989 A0 IL152989 A0 IL 152989A0
Authority
IL
Israel
Prior art keywords
riluzole
preventing
treating
salts
noleukodystrophy
Prior art date
Application number
IL15298901A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Publication of IL152989A0 publication Critical patent/IL152989A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
IL15298901A 2000-06-05 2001-06-05 Use of riluzole or its salts for preventing and treating ?noleukodystrophy IL152989A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007162A FR2809620B1 (fr) 2000-06-05 2000-06-05 Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie
PCT/FR2001/001729 WO2001093802A2 (fr) 2000-06-05 2001-06-05 Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie

Publications (1)

Publication Number Publication Date
IL152989A0 true IL152989A0 (en) 2003-06-24

Family

ID=8850967

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15298901A IL152989A0 (en) 2000-06-05 2001-06-05 Use of riluzole or its salts for preventing and treating ?noleukodystrophy
IL152989A IL152989A (en) 2000-06-05 2002-11-20 Use of riluzole or its salts in the preparation of a medicament for the prevention and treatment of adrenoleukodystrophy

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL152989A IL152989A (en) 2000-06-05 2002-11-20 Use of riluzole or its salts in the preparation of a medicament for the prevention and treatment of adrenoleukodystrophy

Country Status (14)

Country Link
EP (1) EP1299102B1 (de)
JP (1) JP4848117B2 (de)
AT (1) ATE323486T1 (de)
AU (2) AU7419501A (de)
CA (1) CA2409379C (de)
CY (1) CY1107048T1 (de)
DE (1) DE60118924T2 (de)
DK (1) DK1299102T3 (de)
ES (1) ES2260230T3 (de)
FR (1) FR2809620B1 (de)
IL (2) IL152989A0 (de)
MX (1) MXPA02011810A (de)
PT (1) PT1299102E (de)
WO (1) WO2001093802A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
AU1780699A (en) * 1998-01-09 1999-07-26 Mor Research Applications Ltd. Treatment of dyskinesias
EP1065931A4 (de) * 1998-04-02 2006-10-11 Avicena Group Inc Eine kombination einer kreatin-verbindung und eines zweiten stoffes enthaltende zusammensetzungen

Also Published As

Publication number Publication date
FR2809620B1 (fr) 2002-08-02
CA2409379A1 (fr) 2001-12-13
MXPA02011810A (es) 2004-05-17
AU7419501A (en) 2001-12-17
ATE323486T1 (de) 2006-05-15
AU2001274195B2 (en) 2005-12-01
ES2260230T3 (es) 2006-11-01
JP2003535113A (ja) 2003-11-25
DE60118924D1 (de) 2006-05-24
CY1107048T1 (el) 2012-09-26
FR2809620A1 (fr) 2001-12-07
CA2409379C (fr) 2009-08-18
PT1299102E (pt) 2006-08-31
EP1299102A2 (de) 2003-04-09
DE60118924T2 (de) 2007-01-11
WO2001093802A2 (fr) 2001-12-13
IL152989A (en) 2009-08-03
JP4848117B2 (ja) 2011-12-28
WO2001093802A3 (fr) 2002-03-07
DK1299102T3 (da) 2006-08-14
EP1299102B1 (de) 2006-04-19

Similar Documents

Publication Publication Date Title
AU4086101A (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
WO2000038786A3 (en) Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
IL108845A0 (en) Use of anticonvulsants in the treatment of neuro-aids
PT1071422E (pt) Associações de riluzole e levodopa para o tratamento da doença de parkinson
YU82602A (sh) Korišćenje il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
BR0112212A (pt) Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes
GB9804886D0 (en) Therapeutic combination
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
IL152989A0 (en) Use of riluzole or its salts for preventing and treating ?noleukodystrophy
AU5311301A (en) Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis
IL143280A0 (en) Use of riluzole for treating acoustic traumas
WO2002005796A3 (en) Use of a spla2 inhibitor for the treatment of sepsis
AU2001274195A1 (en) Use of riluzole or its salts for preventing and treating adrenoleukodystrophy
AU2001256406A1 (en) Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity
AU2001286228A1 (en) Polymer and its use for the treatment and/or prevention of hyperphosphoremia
AU2001219672A1 (en) Phenoxyethyl-thiourea-pyridine compounds and their use for the treatment of hiv-infections